Akari TherapeuticsAKTX
About: Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Employees: 12
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
40% more funds holding
Funds holding: 10 [Q3] → 14 (+4) [Q4]
0% less ownership
Funds ownership: 0% [Q3] → 0% (-0%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
27% less capital invested
Capital invested by funds: $536K [Q3] → $394K (-$142K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AKTX.
Financial journalist opinion









